Trial reportFrontiers in nutrition2026
The effects of a saffron extract (Affron®) on mood, sleep, self-esteem, and exploratory measures of physical appearance in women aged 50 to 70 years experiencing low mood and poor sleep: a randomised, double-blind, placebo-controlled trial.
Trial report in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Depression is commonly accompanied by sleep disturbances and low self-esteem. Saffron ( Objective: To examine the effects of supplementation with a saffron extract (Affron®) on mood, sleep, self-esteem, and skin health in women aged 50-70 years experiencing low mood and self-reported poor sleep. Methods: In this randomised, double-blind, placebo-controlled trial, 86 women were allocated in a 1:1 ratio to receive either 28 mg/day of a saffron extract or placebo for 12 weeks. The primary outcome was the Depression, Anxiety and Stress Scale-21 (DASS-21) depression subscale. Secondary outcomes included the PROMIS Sleep Disturbance and Sleep-Related Impairment scales, the Rosenberg Self-Esteem Scale, a self-report measure of physical appearance, and facial skin age estimated using an artificial intelligence-based application. Results: Compared with placebo, saffron resulted in greater reductions in DASS-21 depression scores (adjusted mean difference: 2.37; 95% CI: 0.23, 4.51; Conclusion: Supplementation with a saffron extract (Affron®) for 12 weeks was associated with improvements in depressive symptoms. Improvements were also observed in self-esteem and sleep-related impairment; however, these secondary findings should be considered exploratory and require confirmation in adequately powered studies. No significant group differences were observed for sleep disturbance, perceived physical appearance, or estimated facial skin age. Clinical trial registration: https://anzctr.org.au/ACTRN12625000638437p.aspx, ACTRN (registration number): ACTRN12625000638437p.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.